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Introduction {#sec1}
============

Inflammatory bowel disease (IBD) is a chronic, relapsing condition with two main clinicopathological subtypes, Crohn's disease (CD) and ulcerative colitis (UC) ([@bib25]). Susceptibility to IBD is driven by a genetic predisposition to aberrant mucosal responses to commensals ([@bib24], [@bib36], [@bib37]) and characterized by the inappropriate production of a number of pro-inflammatory cytokines and chemokines ([@bib37]). Genome-wide association studies (GWASs) have provided critical insights into disease pathogenesis and implicate a *FCGR2A* variant that alters the binding affinity of the antibody receptor it encodes ([@bib24]). Fc gamma receptors (FcγRs) bind to the Fc portion of immunoglobulin G (IgG), are expressed by many immune cells (including macrophages), and mediate the cellular effector functions of IgG antibodies. These cell-surface glycoproteins include activating receptors (in humans FcγRIIA, IIIA, and IIIB) and a single inhibitory receptor FcγRIIB ([@bib38], [@bib47]). The extent to which IgG immune complexes (ICs) activate immune cells is dependent on the relative engagement of activating or inhibitory FcγRs (the A:I ratio).

Genetic variation in FcγRs can alter the A:I ratio and influence susceptibility to a number of autoimmune diseases ([@bib47]). An *FCGR2A* single-nucleotide polymorphism (SNP) (dbSNP: rs1801274) leading to an amino acid substitution (histidine to arginine at position 131) results in a lower binding affinity for IgG, reducing the A:I ratio ([@bib55]). FcγRIIA-R131 is protective in UC ([@bib24]), suggesting that IgG might play a pathogenic role in intestinal inflammation. Although *in vitro* studies have identified a generic increase in the production of a number of pro-inflammatory cytokines by immune cells in response to IgG ([@bib50]), there is limited insight into the cellular pathways underpinning this genetic association. Furthermore, IgG antibodies are considered less important in intestinal immunity because of the dominance of IgA at mucosal surfaces ([@bib21]).

We found a profound induction of anti-commensal IgG and of activating FcγR signaling in the colonic mucosa in UC patients. The resulting commensal-IgG immune complexes engaged gut-resident FcγR-expressing macrophages, inducing NLRP3- and reactive oxygen species (ROS)-dependent production of IL-1β and neutrophil-recruiting chemokines, and this was modulated by *FCGR2A* genotype. In a murine model of intestinal inflammation, manipulation of macrophage FcγR signal strength determined the magnitude of intestinal inflammation and of IL-1β-dependent induction of type 17 immunity *in vivo*. Our findings provide insight into the mechanisms mediating IgG-FcγR-associated inflammation in UC, which might present therapeutic targets for the treatment of UC.

Results {#sec2}
=======

Anti-commensal IgG Is Associated with the Magnitude of Intestinal Inflammation {#sec2.1}
------------------------------------------------------------------------------

We first sought to interrogate whether there was an increase in local IgG within the gastrointestinal (GI) tract during intestinal inflammation, in line with previous reports ([@bib7], [@bib33], [@bib45], [@bib50]). Analysis of published transcriptomic data of intestinal biopsies from a cohort of patients with clinically active UC demonstrated a significant enrichment of IgM and IgG heavy-chain transcripts within inflamed mucosa ([Figures 1](#fig1){ref-type="fig"}A and [S1](#mmc1){ref-type="supplementary-material"}A). Indeed, upregulation of an *IGH* signature (a cumulative measure of *IGH* expression) was specifically associated with diseased tissue in UC compared with non-diseased UC and healthy control colonic tissue ([Figure S1](#mmc1){ref-type="supplementary-material"}B), implicating humoral responses in disease. Consistent with an increase in local commensal-specific IgG, we observed a significantly higher proportion of luminal commensals bound by IgG in UC stool samples than in household controls, in contrast to IgA-bound microbes ([Figure 1](#fig1){ref-type="fig"}B and [Table S1](#mmc1){ref-type="supplementary-material"}). Notably, samples with higher levels of IgG-bound commensals were found in patients with the highest disease severity scores ([Figure 1](#fig1){ref-type="fig"}C).Figure 1Anti-commensal IgG Is Associated with the Magnitude of Intestinal Inflammation(A) Analysis of human Ig heavy-chain gene transcripts in healthy and UC colonic biopsies. Data were derived from Gene Expression Omnibus (GEO) dataset GEO: [GSE9452](ncbi-geo:GSE9452){#intref0415}.(B) IgG- and IgA1- and IgA2-bound SYBR green^hi^ microbes in UC and household healthy control (HHC) stool samples were analyzed as household pairs (n = 6 per group).(C) Correlation of pooled IgG- and IgA1- and IgA2-bound bacterial levels with clinical activity index (CAI) (n = 12).(D) Murine colon luminal IgG and IgA levels following two cycles of DSS administration (cDSS) and normalized to total protein content (n = 10 per group). Medians are indicated.(E) Quantification of IgG-bound bacteria in stool after a single acute course of 6-day 2% DSS administration (aDSS) or H~2~O with (red) and without (black) paired serum pre-incubation (n = 6--9 per group). Medians are indicated.(F) Correlation of IgG-bound commensals (no serum) from pooled control and colitic mice at day 21 after aDSS with markers of colonic inflammation; length and neutrophil count (n = 20) are shown. In (D)--(F), data are pooled from two independent experiments.(G) Opsonization of commensal bacterial species with day 21 aDSS serum or healthy control serum (day 0) (n = 5 per group). Medians are indicated. Data are representative of two independent experiments.(H) Confocal image of control or inflamed colons from cDSS-treated mice (red, IgG; green, Ki67; white, phalloidin). Data representative of three independent experiments.(I and J) Quantification of IgG- and IgA-expressing IgM^−^ B cell subsets in murine colons (I) and colon-draining MLN (J) at day 21 after aDSS administration versus controls (day 0) (n = 5 per group). For absolute cell-count quantification plots, medians are indicated. Data are representative of three independent experiments.p values were calculated via limma with multiple correction using the Benjamini-Hochberg (BH) procedure (A), ratio paired t test (B), linear regression analysis (C and F), or the nonparametric Mann-Whitney U test (D, E, G, I, and J). ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001, ^∗∗∗∗^p \< 0.0001. See also [Figure S1](#mmc1){ref-type="supplementary-material"} and [Table S1](#mmc1){ref-type="supplementary-material"}.

To probe this phenomenon further, we used dextran sodium sulfate (DSS), a colitogen that leads to osmotic epithelial damage, to induce barrier-breach-associated inflammation. Exposure of mice to two repeated cycles of DSS (referred to here as chronic DSS \[cDSS\]) induced an upregulation of IgG transcripts within the colonic mucosa ([Figure S1](#mmc1){ref-type="supplementary-material"}C), an increase in luminal IgG ([Figure 1](#fig1){ref-type="fig"}D), and a modest increase in IgA, mirroring observations in human UC. Indeed, a single acute 6-day course of 2% DSS (referred to here as acute DSS \[aDSS\]) was sufficient to induce an increase in *de novo* circulating anti-commensal and anti-flagellin IgG, consistent with previous reports ([@bib26]) ([Figure S1](#mmc1){ref-type="supplementary-material"}D). We also observed significantly more luminal microbes bound by IgG at day 7 and day 21 after aDSS exposure than at day 0, and the addition of paired DSS serum further increased bacterial binding by IgG ([Figure 1](#fig1){ref-type="fig"}E), whereas there was no significant increase in IgA-bound bacteria ([Figure S1](#mmc1){ref-type="supplementary-material"}E). The number of luminal IgG-bound microbes correlated with colon length and colonic neutrophil infiltration ([Figure 1](#fig1){ref-type="fig"}F), which are measures of disease severity. Indeed, the level of IgG-opsonized microbes better reflected colitis severity than that of IgA opsonization ([Figure S1](#mmc1){ref-type="supplementary-material"}F), implicating anti-commensal IgG as a determinant of the intestinal inflammatory response. Circulating anti-commensal IgG titers in serum correlated with colonic neutrophil infiltration at day 21 after aDSS exposure ([Figure S1](#mmc1){ref-type="supplementary-material"}G). This serum IgG response was not specific to a single commensal or pathobiont but exhibited broad microbial specificity, including the probiotic *Lactobacillus reuteri* and the pathobiont *Proteus mirabilis* ([Figure 1](#fig1){ref-type="fig"}G), and *L. reuteri* IgG binding correlated most strongly with disease activity of those species tested ([Figure S1](#mmc1){ref-type="supplementary-material"}H). Consistent with an expansion of local IgG production, we observed an increase in IgG-expressing cells within the inflamed submucosa of the colon of cDSS-treated mice ([Figure 1](#fig1){ref-type="fig"}H) and that B cells represented the major lymphocyte population in this setting ([Figure S1](#mmc1){ref-type="supplementary-material"}I). By day 21 after aDSS exposure, there was a pronounced expansion of IgG^+^CD19^+^ B cells within the inflamed colonic lamina propria (LP) ([Figures 1](#fig1){ref-type="fig"}I and [S1](#mmc1){ref-type="supplementary-material"}J) and colon-draining mesenteric lymph nodes (MLNs) ([Figures 1](#fig1){ref-type="fig"}J and [S1](#mmc1){ref-type="supplementary-material"}M). We also observed an increase in CD138^+^ plasma cells within the inflamed colon ([Figure S1](#mmc1){ref-type="supplementary-material"}K) and MLNs ([Figure S1](#mmc1){ref-type="supplementary-material"}N), as well as an increase in the absolute numbers of IgG-expressing plasma cell at both sites ([Figures S1](#mmc1){ref-type="supplementary-material"}L and S1O), indicating that although the transudation of systemic IgG might make a substantial contribution to the luminal commensal-reactive IgG, there is also *de novo* IgG generation locally within the GI tract. Together, these data suggest that in UC there is an increase in intestinal commensal-specific IgG, positioned to activate FcγR-expressing mucosal immune cells, and that DSS colitis provides a reasonable model for interrogating the effects of local IgG in intestinal inflammation.

Activating FcγR Signaling in Intestinal Inflammation {#sec2.2}
----------------------------------------------------

To address the role of FcγR signaling in intestinal inflammation, we analyzed FcγR mRNA expression in mucosal biopsies in published cohorts of UC patients. Activating FcγR gene transcripts, including *FCGR2A* and *FCGR3A/B*, were among the most differentially expressed genes in inflamed UC biopsies compared with UC in remission and non-inflamed UC biopsies and healthy control biopsies (log2 fold change \[FC\] \> 2; [Figures 2](#fig2){ref-type="fig"}A and 2B). In contrast, the inhibitory receptor *FCGR2B* was more modestly induced ([Figure 2](#fig2){ref-type="fig"}B), resulting in an increase in the mucosal FcγR A:I ratio ([Figure S2](#mmc1){ref-type="supplementary-material"}A). UC-associated enrichment was specific to FcγRs and was not observed for other Fc receptors ([Figure S2](#mmc1){ref-type="supplementary-material"}B), and *FCGR* enrichment was confirmed in a further independent UC dataset ([Figure S2](#mmc1){ref-type="supplementary-material"}C). Furthermore, in mucosal UC biopsies taken prior to infliximab intervention ([Table S2](#mmc1){ref-type="supplementary-material"}), elevated *FCGR2A* expression was associated with treatment-refractory disease ([Figure 2](#fig2){ref-type="fig"}C) and was predictive of subsequent resistance to tumor necrosis factor-α (TNF-α) blockade ([@bib3], [@bib4]) ([Figure 2](#fig2){ref-type="fig"}D).Figure 2Activating FcγR Signaling in Intestinal Inflammation(A) Analysis of the top significantly differentially expressed genes (log2 FC \> 2) in human active UC mucosal biopsies compared with controls. Data are from GEO: [GSE38713](ncbi-geo:GSE38713){#intref0420}.(B) *FCGR* enrichment in inflamed active UC (n = 15) compared with healthy control (n = 13), remission (n = 8), and non-inflamed mucosal biopsies (n = 7). Data are from GEO: [GSE38713](ncbi-geo:GSE38713){#intref0425}.(C) *FCGR* expression in colonic biopsies from UC patients refractory (n = 16) or responsive (n = 8) to infliximab treatment and healthy controls prior to treatment initiation (n = 6). Data are from GEO: [GSE16879](ncbi-geo:GSE16879){#intref0430}. Minimum to maximum box-and-whisker plots are shown in (B) and (C).(D) Area under the receiver operator curve (AUROC) analysis for *FCGR2A* expression in infliximab-refractory mucosal biopsies compared with infliximab-responsive biopsies. Data were derived as in (C).(E) Gene-set enrichment analysis (GSEA) of the KEGG FcγR*-*mediated phagocytosis pathway in UC and healthy colonic biopsies (left) and cDSS-inflamed and healthy murine colons (bottom). Data are from GEO: [GSE38713](ncbi-geo:GSE38713){#intref0435} (UC = 15, HC = 13) and GEO: [GSE42768](ncbi-geo:GSE42768){#intref0440} (cDSS = 5, H~2~O = 5).(F) FcγR expression by murine colonic leukocytes at day 7 after aDSS. Data are representative of 3 independent experiments.(G) qPCR of FcγR mRNA expression in flow-sorted murine colonic CX3CR1^+^Ly6C^lo^MHC-II^hi^ macrophages, as identified in (F). Data are representative of 2 independent experiments.(H) Single-cell RNA-seq of immune cell subsets in healthy human colon. Data are from GEO: [GSE81861](ncbi-geo:GSE81861){#intref0445}. The heatmap illustrates the top 50 cell-type-specific markers ranked by AUROC score.(I) qPCR of FcγR mRNA expression in flow-sorted human ileal CD14^+^CX3CR1^+^SSC^int^ macrophages.(J) Colonic "monocyte waterfall" subset quantification by flow cytometry at day 7 after aDSS versus controls (n = 3 per group). Flow plots of CD11b^+^CX3CR1^+^ waterfall subsets (left) and quantification of absolute cell counts for the indicated subsets (right) are shown. For absolute cell counts, medians are indicated. Data are representative of 3 independent experiments.(K) FcγR quantification of CX3CR1^+^Ly6C^lo^MHC-II^hi^ macrophages, as shown in (J), by flow cytometry. Means ± SEM are indicated and normalized to the A:I ratio of control-treated mice.Data are representative of two independent experiments. p values were calculated via limma with multiple correction using the BH procedure (A--C), AUROC analysis (D and H), or Student's two-tailed t test (J and K). ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001, ^∗∗∗∗^p \< 0.0001. See also [Figure S2](#mmc1){ref-type="supplementary-material"} and [Table S2](#mmc1){ref-type="supplementary-material"}.

The functional effect of a higher A:I ratio at a cellular level is to reduce the activation threshold, increasing the likelihood of activation upon IgG IC encounter. In keeping with this, we found an enrichment of genes associated with FcγR-mediated phagocytosis in UC biopsies compared with control biopsies ([Figure 2](#fig2){ref-type="fig"}E), a unique pathway distinct from TLR-signaling genes ([Figure S2](#mmc1){ref-type="supplementary-material"}D). Using both a published transcriptomics dataset and confirmatory qPCR, analysis of colonic FcγR expression in cDSS-treated mice demonstrated a similar increase in FcγR transcripts ([Figure S2](#mmc1){ref-type="supplementary-material"}E) and enrichment of FcγR activation pathway genes ([Figure 2](#fig2){ref-type="fig"}E). In contrast, a consistent enrichment of FcγR genes or FcγR signaling pathways in *Citrobacter rodentium* infection was not observed ([Figure S2](#mmc1){ref-type="supplementary-material"}F), suggesting that our observations might be specific to DSS-induced colitis.

A number of immune cell subsets, including macrophages, dendritic cells (DCs), and neutrophils, express FcγRs. During aDSS-induced inflammation, when compared with other colonic-resident immune cells (as identified in [Figure S2](#mmc1){ref-type="supplementary-material"}G), intestinal macrophages (CD11b^+^CX3CR1^+^Ly6C^lo^MHC-II^+^F4/80^+^) expressed the highest levels of both activating and inhibitory FcγRs ([Figure 2](#fig2){ref-type="fig"}F). In particular, FcγRIII (the murine ortholog of FcγRIIA) was highly expressed at both the transcript and protein levels ([Figures 2](#fig2){ref-type="fig"}F and 2G). To investigate FcγR expression in the human intestine, we made use of a recently published single-cell RNA sequencing (scRNA-seq) dataset generated from human colon. Immune cell subsets were identified through canonical-marker gene expression and alignment with human peripheral-blood mononuclear cell (PBMC) single-cell transcriptomic data ([Figure S2](#mmc1){ref-type="supplementary-material"}H). Analysis of colonic single-cell transcriptomes indicated that *FCGR2A* and *FCER1G* were highly specific to the mononuclear phagocyte (MNP) cluster ([Figure 2](#fig2){ref-type="fig"}H), transcriptionally similar to circulating CD14^+^ classical monocytes ([Figure S2](#mmc1){ref-type="supplementary-material"}H). Indeed, FcγRIIA was confirmed as the dominant FcγR expressed by CD14^+^CX3CR1^+^ macrophages flow sorted from the human intestine ([Figures 2](#fig2){ref-type="fig"}I, [S2](#mmc1){ref-type="supplementary-material"}I, and S2J). The increase in activating *FCGR2A* transcripts observed in colonic biopsies in UC might be due to an increase in the number of FcγR-expressing macrophages during inflammation or the upregulation of activating FcγR expression on resident macrophages. The adult intestinal macrophage pool is largely derived from circulating monocytes in homeostasis and inflammation ([@bib6]). Analysis of the CD11b^+^CX3CR1^+^ "monocyte waterfall" ([@bib48]) demonstrated an influx of colonic monocytes and an increase in newly differentiated inflammatory Ly6C^+^MHC-II^int^ macrophages and mature Ly6C^lo^MHC-II^hi^ macrophages at day 7 after aDSS ([Figure 2](#fig2){ref-type="fig"}J). Furthermore, activating FcγR expression was augmented on these cells, increasing their A:I ratio ([Figure 2](#fig2){ref-type="fig"}K) and rendering them more susceptible to IgG-mediated activation. Together, these data show that the intestinal MNP system is primed to respond to the emergence of local IgG after the onset of intestinal inflammation.

Mucosal FcγR Expression Correlates with IL-1β and CXCL8 {#sec2.3}
-------------------------------------------------------

To understand the specific molecular pathways that mediate FcγR-induced intestinal inflammation in UC, we first sought to identify common inflammatory networks present in colonic biopsies across multiple UC cohorts and then to interrogate correlations with *FCGR2A*. Analysis of significantly enriched cytokines and chemokines (adjusted p value \< 0.05) within inflamed UC mucosal biopsies revealed that *IL1B* and neutrophil-recruiting chemokines, including *CXCL1* and *CXCL8*, were among the most significantly upregulated genes compared with those within controls ([Figures 3](#fig3){ref-type="fig"}A and [S3](#mmc1){ref-type="supplementary-material"}A). Of these genes, *IL1B* and *CXCL8* correlated most strongly with *FCGR2A* ([Figures 3](#fig3){ref-type="fig"}B, 3C, and [S3](#mmc1){ref-type="supplementary-material"}B). We also observed a correlation between these genes and *IGHG1* expression ([Figure S3](#mmc1){ref-type="supplementary-material"}C). To further examine gene expression associations in an unbiased manner, we performed hierarchical clustering of all chemokine and cytokine gene transcripts and *FCGR2A* within these same cohorts. Strikingly, this placed *IL1B* in a cluster with, and adjacent to, *FCGR2A* ([Figures 3](#fig3){ref-type="fig"}D and [S3](#mmc1){ref-type="supplementary-material"}D). In cDSS colitis, as in UC biopsies, *Il1b* was the most highly induced cytokine gene within the inflamed colon, as assessed by transcriptomic analysis, and displayed higher total expression than did other inflammatory mediators, as shown by qPCR, suggesting a dominant role for this cytokine in colitis ([Figure S3](#mmc1){ref-type="supplementary-material"}E). Furthermore, its expression closely correlated with *Fcgr3* transcript expression within whole colonic tissue by qPCR ([Figure 3](#fig3){ref-type="fig"}E), as did *Cxcl1* and *Cxcl2* (murine neutrophil-recruiting chemokines; [Figure 3](#fig3){ref-type="fig"}F). Together, these data demonstrate that the expression of FcγRIIA and IL-1β are closely associated during colitis and raise the possibility that anti-commensal IgG might contribute to intestinal inflammation via FcγR-dependent induction of IL-1β, a Th17-polarizing cytokine ([@bib14], [@bib46]), and neutrophil-recruiting chemokines.Figure 3Mucosal FcγR Expression Correlates with IL-1β and CXCL8(A) Log2 fold-change comparison of differentially expressed cytokine and chemokine genes across two independent UC cohorts. Data are from GEO: [GSE38713](ncbi-geo:GSE38713){#intref0450} (UC = 15, HC = 13) and GEO: [GSE59071](ncbi-geo:GSE59071){#intref0455} (UC = 74, HC = 11).(B and C) Correlation summary of *FCGR2A* expression with UC-associated cytokine and chemokine gene transcripts (B) and correlation with *IL1B* and *CXCL8* (C) in n = 85 mucosal biopsies. Data are from GEO: [GSE59071](ncbi-geo:GSE59071){#intref0460}.(D) Hierarchical clustering of cytokine and chemokine and *FCGR2A* expression in healthy controls and non-inflamed and inflamed UC patients. Data are derived from GEO: [GSE38713](ncbi-geo:GSE38713){#intref0465}.(E and F) Correlation of *Fcgr3* expression with *Il1b* (E) and candidate-gene (F) expression in whole inflamed colonic tissue by qPCR (n = 16). Data are representative of two independent experiments.(G) *IL1B* and *CXCL8* expression in healthy human LPMC stimulated with Ova or Ova-IC for 16 h (n = 5 per condition). Means ± SEM are indicated. Data are representative of two independent experiments.(H) IL-1β, CXCL1, and CXCL2 in supernatants of inflamed murine LPMCs stimulated with Ova or Ova-IC for 16 h (n = 3-9). Paired samples represent LPMCs from a single mouse. Data are pooled from two independent experiments.(I) Flow-cytometry profiling of pro-IL-1β-expressing cells at day 14 after aDSS (n = 6). Medians are indicated. Data are representative of three independent experiments.(J) Pro-IL-1β expression by colonic CX3CR1^+^ MNP subsets and neutrophils in *Rag2*^−/−^ mice treated with control or anti-flagellin-enriched serum IgG and 7-day aDSS or uninflamed H~2~O-treated controls (n = 5 per group). Medians are indicated.(K) Day 7 weight loss for aDSS-treated mice shown in (J) (n = 5 per group). Medians are indicated.p values were calculated via limma with multiple correction using the BH procedure (A), linear regression analysis (B, C, E, and F), Student's two-tailed t test (G), ratio paired t test (H and I), or the Kruskal-Wallis test with Dunn's multiple-comparisons test (J). ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001, ^∗∗∗∗^p \< 0.0001. See also [Figure S3](#mmc1){ref-type="supplementary-material"}.

To determine whether IgG and activating FcγR signaling and these key cytokines and chemokines might be causatively linked, we isolated human gut LP mononuclear cells (LPMCs) and stimulated them with IgG IC *ex vivo* to directly cross-link FcγRs. This resulted in a significant induction of *IL1B* and *CXCL8* ([Figure 3](#fig3){ref-type="fig"}G). Similarly, *ex vivo* stimulation of murine LPMCs from aDSS-treated mice with IgG ICs resulted in an increase in IL-1β, CXCL1, and CXCL2 production ([Figure 3](#fig3){ref-type="fig"}H). *In vivo*, passive transfer of anti-commensal IgG further enhanced *Il1b*, *Cxcl1*, and *Cxcl2* transcript levels within the colon after 7-day aDSS ([Figure S3](#mmc1){ref-type="supplementary-material"}F). Together, these data support the hypothesis that commensal IgG directly drives intestinal inflammation via induction of pro-inflammatory cytokines and chemokines on resident intestinal immune cells. Intracellular cytokine staining of murine LPMCs demonstrated that CD11b^+^CX3CR1^+^ cells (population A), comprising intestinal mononuclear phagocytes (MNPs), were the dominant source of IL-1β during colitis, with a minor contribution from neutrophils ([Figure 3](#fig3){ref-type="fig"}I), consistent with our analysis of human colonic scRNA-seq data, showing that *IL1B* expression is specific to the MNP cluster ([Figure 2](#fig2){ref-type="fig"}H). Indeed, flow-sorted murine colonic macrophages stimulated with IgG ICs *ex vivo* demonstrated substantial induction of IL-1β, CXCL1, and CXCL2 expression ([Figure S3](#mmc1){ref-type="supplementary-material"}G). Finally, we immunized and boosted C57BL/6 mice to generate high titers of circulating anti-flagellin IgG ([Figure S3](#mmc1){ref-type="supplementary-material"}H). Transfer of this anti-flagellin-enriched serum IgG into naive IgG-deficient *Rag2*^−/−^ mice prior to aDSS significantly augmented pro-IL-1β expression by colonic CX3CR1^+^ MNP subsets, particularly Ly6C^hi^ monocytes and Ly6C^+^MHC-II^int^ inflammatory macrophages ([Figure 3](#fig3){ref-type="fig"}J) and was associated with increased weight loss ([Figures 3](#fig3){ref-type="fig"}K and [S3](#mmc1){ref-type="supplementary-material"}I). In contrast, no difference in colonic neutrophil pro-IL-1β expression was observed, suggesting that FcγR signaling drives pro-IL-1β expression by colonic MNPs and is sufficient to induce inflammation in the absence of adaptive immune cells.

IgG-Induced IL-1β Production by Human Macrophages {#sec2.4}
-------------------------------------------------

We next sought to further interrogate the role of FcγR signaling in intestinal macrophage function. A cell-intrinsic effect of IgG ICs on macrophage, cytokine, and chemokine production was evident as FcγR cross-linking on flow-sorted murine CX3CR1^+^Ly6C^lo^MHC-II^hi^ colonic macrophages induced widespread changes in gene expression ([Figure S4](#mmc1){ref-type="supplementary-material"}A), including 264 genes that were significantly differentially expressed in UC biopsies ([Figure 4](#fig4){ref-type="fig"}A). IC-induced genes were enriched in UC-relevant immune pathways, such as neutrophil chemotaxis ([Figure S4](#mmc1){ref-type="supplementary-material"}B), and included key UC-associated cytokines such as *Il1b*, *Il23a*, and the recently characterized *Osm* ([@bib54]) ([Figures 4](#fig4){ref-type="fig"}A and [S4](#mmc1){ref-type="supplementary-material"}C). Given our previous analyses demonstrating the predominance of *IL1B* expression in inflamed UC biopsies, that its expression is closely linked to that of *FCGR2A*, and that *IL1B* is induced in lamina propria MNP after FcγR engagement ([Figure 3](#fig3){ref-type="fig"}), we sought to determine the molecular pathway linking FcγR cross-linking and IL-1β production. FcγR signaling resulted in the induction of genes involved in NLRP3 inflammasome priming and activation in murine colonic macrophages, including *Nlrp3* ([Figures 4](#fig4){ref-type="fig"}B and [S4](#mmc1){ref-type="supplementary-material"}D), suggesting that IgG-associated IL-1β production by intestinal macrophages might be dependent on the NLRP3 inflammasome. Inflammasome assembly is a two-step process; "signal 1" is required for NLRP3 transcription, and "signal 2", including stimuli such as adenosine trisphosphate (ATP) and ROS, for the generation of a multimeric-complex-containing NLRP3, ASC, and pro-caspase-1 ([@bib43]). Priming of murine bone-marrow-derived macrophages (BMDMs) with IgG ICs, followed by ATP, resulted in IL-1β secretion in wild-type (WT) but not *Nlrp3*-deficient macrophages ([Figure 4](#fig4){ref-type="fig"}C). This induction was greater than either model antigen (Ova) or anti-Ova immune serum stimulation alone ([Figure S4](#mmc1){ref-type="supplementary-material"}E). IgG IC stimulation of human monocyte-derived macrophages (MDMs) in the presence of a fecal commensal suspension or lipopolysaccharide (LPS) was sufficient to induce mature IL-1β secretion, an effect almost entirely abrogated by blockade of the UC-associated receptor FcγRIIA ([Figures 4](#fig4){ref-type="fig"}D and [S4](#mmc1){ref-type="supplementary-material"}F). Both IgG-IC and fecal commensals were effective in inducing *IL1B* transcript and pro-IL-1β protein expression ([Figure 4](#fig4){ref-type="fig"}E). IgG IC alone was insufficient to generate cleaved IL-1β, and although stimulation with fecal commensals resulted in the production of some mature IL-1β, only the combined stimulation of IgG ICs and fecal commensals was effective in driving substantial cleavage of pro-IL-1β to mature IL-1β ([Figure 4](#fig4){ref-type="fig"}E). This demonstrates that FcγR cross-linking provides a robust priming "signal 1" for NLRP3 inflammasome assembly. To test the extent to which IL-1β production was dependent on NLRP3 in human macrophages, we performed NLRP3 protein knockdown via the "Trim-Away" technique ([Figure 4](#fig4){ref-type="fig"}F) ([@bib17]). This substantially abrogated IgG-induced macrophage IL-1β production, as did the addition of an NLRP3 inhibitor MCC950 ([Figure 4](#fig4){ref-type="fig"}F). IL-1β production by human MDMs after combined stimulation of IgG ICs and commensals or LPS was also reduced by the addition of MitoTEMPO, a mitochondrial ROS inhibitor ([Figures 4](#fig4){ref-type="fig"}G and [S4](#mmc1){ref-type="supplementary-material"}G). Together, these data suggest that in UC, IgG-commensal ICs cross-link intestinal macrophage FcγRIIA and thus result in NLRP3-dependent IL-1β production.Figure 4IgG-Induced IL-1β Production by Human Macrophages(A) Venn diagram of significant co-expressed genes between UC and Ova-IC-stimulated colonic macrophages (left) and IC-induced UC-associated cytokines and chemokines (right), as determined by sdef. Human UC data are from GEO: [GSE38713](ncbi-geo:GSE38713){#intref0470} (UC = 15, HC = 13). For macrophage stimulation, n = 4 per condition.(B) GSEA of inflammasome genes (left) and heatmap of selected core enrichment genes (right) in flow-sorted murine intestinal CX3CR1^+^Ly6C^lo^MHC-II^hi^ macrophages stimulated with Ova and Ova-IC for 4 h (n = 4 per condition).(C) IL-1β production by WT and *Nlrp3*^−/−^ BMDMs primed with Ova and Ova-IC for 4 h followed by 30 min of ATP stimulation (^∗∗∗∗^, WT versus *Nlrp3*^−/−^ Ova-IC; \#\#\#\#, WT Ova versus Ova-IC) (n = 3 per condition). Means ± SEM are indicated. Data are representative of three independent experiments. ND, not detected.(D) IL-1β ELISA of human MDMs stimulated with plate-coated IgG (c-IgG) and intestinal commensals (Comm.) for 24 h ± anti-FcγRIIA IgG-blocking antibody (n = 3 per condition). Means ± SEM are indicated. Data are representative of two independent experiments.(E) qPCR of *IL1B* mRNA (left, n = 3 per condition) and western blot of IL-1β in cell lysates and cell-free supernatants (right) from human MDMs as stimulated in (D). For qPCR (left), means ± SEM are indicated. Data are representative of two independent experiments.(F) The effect of NLRP3 inhibition on IgG-induced MDM IL-1β production. Western blot (left) and IL-1β production (left, ELISA) by human MDMs stimulated as in (D) after NLRP3 "Trim-Away" or ± NLRP3 inhibitor MCC950 (right, ELISA) (n = 3 per condition). Means ± SEM are indicated.(G) IL-1β production by human MDMs stimulated as in (D) ± mitochondrial ROS inhibitor mitoTEMPO (n = 3 per condition). Means ± SEM are indicated. Data are representative of 2 independent experiments.(H) Fold change in *IL1B* expression in Ova-IC-stimulated MDMs, normalized to R/R fold change (n = 6 per group). Data are pooled from 3 independent experiments. Medians are indicated.(I) Schematic of FcγR A:I ratios with *FCGR2A* SNP (dbSNP: rs1801274) and murine transgenic models.(J) *Il1b* induction in WT, *Fcgr2b*^−/−^, and M-TG BMDMs stimulated with Ova and Ova-IC for 3 h (n = 3 per condition). Means ± SEM are indicated. Data are representative of 3 independent experiments.p values were calculated via the standard DESeq2 method with multiple correction using the BH procedure (A and B), two-way ANOVA with Tukey's multiple comparisons test (C, F, and J), one-way ANOVA with Tukey's multiple-comparisons test (D, E, and G), or parametric Student's t test (H). ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001, ^∗∗∗∗^p \< 0.0001. See also [Figure S4](#mmc1){ref-type="supplementary-material"}.

To link these observations to the genetic variants associated with UC, we investigated the impact of the FcγRIIA-H/R131 SNP on macrophage IL-1β production. After stimulation with IgG ICs, we observed higher *IL1B* expression in MDMs obtained from subjects with the FcγRIIA-H/H131 genotype than in FcγRIIA-R/R131 macrophages ([Figure 4](#fig4){ref-type="fig"}H), demonstrating that this SNP, and the functional effect it confers on the FcγR A:I ratio, determines the magnitude of IL-1β induction in this context. Modeling FcγRIIA function *in vivo* is challenging because mice do not express FcγRIIA, and mice deficient in the orthologous receptor *Fcgr3* have a complete loss of activating signaling from this receptor, which does not reflect the graded functional effect of the FcγRIIA-H/R131 SNP. Our analysis of intestinal macrophages demonstrated that FcγR expression is dominated by the single inhibitory FcγRIIB in both mice and humans and one functionally homologous low-affinity activating FcγR (FcγRIII in mice and FcγRIIA in humans) ([Figures 2](#fig2){ref-type="fig"}G and 2I). Therefore, we used mice with intact activating FcγR signaling but a variable FcγR A:I ratio due to absent, WT, or high-inhibitory-receptor expression, allowing interrogation of the effect of graded activating FcγR signaling strength on intestinal inflammation ([Figure 4](#fig4){ref-type="fig"}I). *In vitro*, IgG IC stimulation of BMDM from mice with a low FcγR A:I ratio due to macrophage-specific overexpression of FcγRIIB ([@bib12]) (macrophage-transgenic \[M-TG\]) resulted in lower *Il1b* induction than in BMDM from WT mice, in contrast to BMDM from mice with a high A:I ratio due to FcγRIIB deficiency, in which *Il1b* induction was significantly higher than in WT mice ([Figure 4](#fig4){ref-type="fig"}J), in a manner analogous to the FcγRIIA-H/R131 variant ([Figures 4](#fig4){ref-type="fig"}H and 4I). Similar results were observed for *Cxcl1* and *Cxcl2* ([Figure S4](#mmc1){ref-type="supplementary-material"}H). We concluded, therefore, that these mice represent a useful model for studying the effects of differing FcγR A:I ratios *in vivo*.

MNP FcγR A:I Ratio Modulates Intestinal Inflammation {#sec2.5}
----------------------------------------------------

Compared with co-housed WT controls, *Fcgr2b*^−/−^ mice subjected to aDSS had a more severe disease course, including impaired weight recovery from day 7 onward ([Figure 5](#fig5){ref-type="fig"}A), a time point at which there is significant induction of anti-commensal IgG ([Figure 1](#fig1){ref-type="fig"}E). Similarly, in an independent experiment, *Fcgr2b*^−/−^ mice had more severe disease than co-housed, littermate WT controls, with *Fcgr2b*^*+/−*^ demonstrating an intermediate phenotype ([Figure S5](#mmc1){ref-type="supplementary-material"}A). Compared with mice reconstituted with WT bone marrow, WT mice reconstituted with *Fcgr2b*^−/−^ bone marrow also showed increased susceptibly to more severe disease after exposure to aDSS ([Figure S5](#mmc1){ref-type="supplementary-material"}B). After aDSS treatment, *Fcgr2b*^−/−^ mice had increased colon and spleen weights and lymph node and spleen enlargement ([Figure S5](#mmc1){ref-type="supplementary-material"}C), as well as marked infiltration of CD45^+^ cells into the colonic mucosa and submucosa in comparison with those of co-housed WT controls ([Figure 5](#fig5){ref-type="fig"}B). This infiltration included neutrophils ([Figure 5](#fig5){ref-type="fig"}C), indicative of on-going inflammation 3 weeks after exposure to aDSS. Inflamed *Fcgr2b*^−/−^ colons had higher levels of *Il1b* transcripts ([Figure S5](#mmc1){ref-type="supplementary-material"}D) and increased numbers of pro-IL-1β-expressing cells than WT controls ([Figure S5](#mmc1){ref-type="supplementary-material"}E). We observed significantly higher proportions of pro-IL-1β^+^ colonic CX3CR1^+^ MNPs in *Fcgr2b*^−/−^ mice than in WT counterparts, particularly in newly recruited Ly6C^hi^ monocytes and Ly6C^+^MHC-II^+^ macrophages ([Figures 5](#fig5){ref-type="fig"}D, 5E, and [S5](#mmc1){ref-type="supplementary-material"}F), as well as minimal pro-IL-1β expression in colonic neutrophils ([Figure S5](#mmc1){ref-type="supplementary-material"}G). Furthermore, flow-sorted colonic MHC-II^+^ MNPs isolated from *Fcgrb*^−/−^ mice with aDSS had increased *Cxcl1* and *Cxcl2* transcripts compared with those obtained from co-housed WT mice ([Figure 5](#fig5){ref-type="fig"}F), consistent with our observations *in vitro*.Figure 5MNP FcγR A:I Ratio Modulates Intestinal Inflammation(A) Weight loss in co-housed sex-matched WT (black circles, n = 8) and *Fcgr2b*^−/−^ (red circles, n = 9) mice after a single 6-day course of 2% DSS. Means ± SEM are indicated. Data are representative of 3 independent experiments.(B) Confocal microscopy of colonic CD45^+^ leukocytes in mice treated as in (A). Data are representative of 2 independent experiments.(C) Flow-cytometric quantification of colonic neutrophil frequency (top) and absolute neutrophil counts (bottom) in WT and *Fcgr2b*^−/−^ colons at day 25 after aDSS (n = 5--7 per group) or in healthy controls (day 0) (n = 3--5 per group). Medians are indicated. Data are representative of 3 independent experiments.(D) Pro-IL-1β expression by colonic CD11b^+^CX3CR1^+^ MNPs at day 25 after aDSS (n = 5--7 per group).(E) Frequency of pro-IL-1β expression within the Ly6C^hi^MHC-II^−^ monocyte and Ly6C^+^MHC-II^int^ macrophage populations as shown in aDSS (n = 5--7 per group) versus controls (day 0) (n = 3--5 per group). Medians are indicated. Data are representative of 3 independent experiments.(F) Chemokine mRNA levels in flow-sorted Ly6C^lo^MHC-II^hi^ colonic macrophages at day 21 after aDSS (n = 4--5 per group). Data normalized to WT mRNA levels. Medians are indicated.(G and H) Weight loss (G) and clinical colonic and lymphoid organ features (H) of co-housed sex-matched M-TG (green circles, n = 5 or 6) and N-TG littermate controls (black circles, n = 6) after aDSS or in healthy controls (day 0 in H). Means ± SEM (weight loss) and medians (colon, MLN, and spleen weight) are indicated. Data are representative of 3 independent experiments.(I) Flow-cytometric quantification of colonic neutrophil frequency (top) and absolute neutrophil count (bottom) in N-TG and M-TG mice at day 21 after aDSS (n = 6 per group) versus controls (day 0) (n = 5--6 per group). Medians are indicated.(J) Pro-IL-1β expression by colonic CX3CR1^+^ MNP subsets in N-TG and M-TG mice treated as in (I) (n = 5 or 6 per group).(K) Frequency (top) and absolute cell count (bottom) of pro-IL-1β-expressing MNP subsets in N-TG and M-TG mice treated as in (I). Medians are indicated. Data are representative of two independent experiments.p values calculated using a two-way ANOVA with Bonferroni's multiple comparisons test (A and G), or the nonparametric Mann-Whitney U test (C-F, H-K). ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001, ^∗∗∗∗^p \< 0.0001. See also [Figure S5](#mmc1){ref-type="supplementary-material"}.

Next, we investigated intestinal pathology in FcγRIIB-M-TG mice and confirmed increased FcγRIIB expression on colonic MNPs and that there was no difference in activating FcγRs ([Figure S5](#mmc1){ref-type="supplementary-material"}H) or in FcγRIIB expression on colonic neutrophils, DCs, B cells, or epithelial cells in FcγRIIB-M-TG mice compared with non-transgenic (N-TG) controls ([Figure S5](#mmc1){ref-type="supplementary-material"}I). After exposure to aDSS, in contrast to *Fcgr2b*^−/−^ mice, FcγRIIB-M-TG mice had a less severe clinical disease course than did N-TG controls, as evidenced by lower weight loss ([Figure 5](#fig5){ref-type="fig"}G), lower colonic and MLN weight ([Figure 5](#fig5){ref-type="fig"}H), and a trend toward increased colon length ([Figure S5](#mmc1){ref-type="supplementary-material"}J), but no difference in spleen size ([Figure 5](#fig5){ref-type="fig"}H). Colonic neutrophil infiltration was also significantly reduced in M-TG mice, consistent with improved disease resolution ([Figure 5](#fig5){ref-type="fig"}I). There was a trend toward reduced global *Il1b*, *Cxcl1*, *Cxcl2*, and *Ccl2* transcripts within the colons of these mice ([Figure S5](#mmc1){ref-type="supplementary-material"}K), whereas pro-IL-1β protein was significantly reduced in intestinal CX3CR1^+^ MNPs in FcγRIIB-M-TG mice ([Figures 5](#fig5){ref-type="fig"}J, 5K, and [S5](#mmc1){ref-type="supplementary-material"}L).

Given that FcγRIIB modulates the B cell activation threshold, we profiled B cell class switching and commensal-reactive IgG responses in our mouse models. We observed an increase in frequency and count of class-switched B cells in the MLN and spleen of *Fcgr2b*^−/−^ mice but no difference in total anti-commensal IgG titer after aDSS ([Figures S5](#mmc1){ref-type="supplementary-material"}M and S5O). We observed no significant difference in class-switched B cells between the MLN of FcγRIIB-M-TG animals at day 21 after aDSS and the MLN of N-TG mice and found similar levels of anti-commensal IgG titers between these two strains ([Figures S5](#mmc1){ref-type="supplementary-material"}N and S5O). Together, these data demonstrate that the differences observed in macrophage IL-1β and disease severity in mice with differing FcγR A:I ratio are not related to differences in the titers of anti-commensal IgG.

MNP FcγR A:I Ratio Modulates Intestinal Type 17 Immunity {#sec2.6}
--------------------------------------------------------

GWASs have implicated the IL-23-IL-17A cytokine axis in both CD and UC ([@bib13]). IL-17A is expressed in healthy mucosa and contributes to intestinal homeostasis, but in excess might promote inflammation ([@bib28]). Th17 cells are key producers of IL-17A within the intestine, and inhibition of these cells can reduce intestinal inflammation ([@bib56]). As well as T-cell-independent effects, a key biological effect of IL-1β is to induce the differentiation and maintenance of Th17 cells ([@bib14], [@bib46]). Given that our data demonstrated that IgG ICs potently induce IL-1β production in intestinal macrophages in mouse and human and that IgG-IC-stimulated colonic macrophages exhibit a Th17-polarizing phenotype ([Figure S6](#mmc1){ref-type="supplementary-material"}A), we sought to determine whether macrophage FcγR A:I ratio was sufficient to affect intestinal type 17 immunity. Analysis of UC biopsies identified a significant positive correlation between *IL17A* and *FCGR2A* ([Figure S6](#mmc1){ref-type="supplementary-material"}B). Furthermore, IgG IC stimulation of inflamed colonic LPMCs resulted in the production of type-17-associated cytokines, including IL-17, granulocyte-macrophage colony-stimulating factor (GM-CSF), and IL-22 ([Figure 6](#fig6){ref-type="fig"}A). *In vivo*, the magnitude of intestinal type 17 responses was determined by the FcγR A:I ratio; in *Fcgr2b*^−/−^ mice, we observed an increase in colonic *Il17a*, *Csf2*, and *Il22* transcripts after aDSS ([Figure 6](#fig6){ref-type="fig"}B), whereas there was little change in global *Ifng* levels ([Figure S6](#mmc1){ref-type="supplementary-material"}C). Intracellular cytokine staining of colonic CD3ε^+^ T cell subsets ([Figure S6](#mmc1){ref-type="supplementary-material"}D) demonstrated a significant increase in the frequency ([Figure 6](#fig6){ref-type="fig"}C) and absolute cell count ([Figure 6](#fig6){ref-type="fig"}D) of both IL-17A^+^ γδ and αβ CD4^+^ T cell subsets in the recovery phase of aDSS colitis. We also observed a significant increase in IL-22 production by these T cell subsets ([Figures S6](#mmc1){ref-type="supplementary-material"}E and S6F), although the magnitude of this response was less than for IL-17A. Globally, there was a significant correlation between *Il1b* and type 17 cytokine gene transcript levels in inflamed colons ([Figure S6](#mmc1){ref-type="supplementary-material"}G), suggesting that FcγR-induced type 17 responses might be IL-1β dependent.Figure 6MNP FcγR A:I Ratio Modulates Intestinal Type 17 Immunity(A) Type-17-associated cytokine production by day-14 LPMCs stimulated with Ova and Ova-IC for 16 h (n = 5--9). Paired samples represent cells isolated from the same mouse. Data are pooled from 2 independent experiments.(B) qPCR of type 17 cytokines in WT and *Fcgr2b*^−/−^ whole colonic tissue after cDSS versus controls (n = 4--9 per group). Data are normalized to uninflamed healthy colon. Medians are indicated. Data are representative of 2 independent experiments.(C) Flow-cytometry plots of colonic IL-17A-expressing T cell subsets in co-housed sex-matched WT and *Fcgr2b*^−/−^ mice at day 21 after aDSS (n = 6--8 per group) versus controls (day 0) (n = 3--5 per group).(D) Quantification of absolute numbers of colonic IL-17A-producing T cells shown in (C). Medians are indicated. Data are representative of 3 independent experiments.(E) Quantification of absolute numbers of colonic IL-17A-producing T cell subsets in co-housed WT and *Fcgr2b*^−/−^ mice at day 15 after aDSS and weekly treatment with anti-IL-1R1 IgG-blocking antibody or control IgG (n = 5--7 per group). Medians are indicated. Data are representative of two independent experiments.(F) Colonic IL-17A-expressing T cell subsets in M-TG and N-TG littermate controls at day 21 after aDSS (n = 5 or 6 per group) versus controls (n = 5 or 6 per group). Data are representative of two independent experiments.(G) Quantification of absolute cell counts of colonic IL-17A-producing T cell subsets as shown in (F). Medians are indicated.(H) Weight loss of *Fcgr2b*^−/−^ mice treated with control or anti-IL-1R1 IgG antibodies after aDSS treatment (n = 5--7 per group). Mean ± SEM are indicated. Data are representative of two independent experiments.(I) Colonic neutrophil infiltration in WT and *Fcgr2b*^−/−^ mice treated as in (H) (n = 5--7 per group). Medians are indicated.p values were calculated with a ratio paired t test (A), the nonparametric Mann-Whitney U test (B--G and I), or a two-way ANOVA (H). ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001, ^∗∗∗∗^p \< 0.0001. See also [Figure S6](#mmc1){ref-type="supplementary-material"}.

In support of this, augmented IL-17A production by T cells in *Fcgr2b*^−/−^ mice was completely abrogated by treatment with an anti-IL-1R1-blocking antibody ([Figures 6](#fig6){ref-type="fig"}E and [S6](#mmc1){ref-type="supplementary-material"}H), as was the increase in IL-22 ([Figure S6](#mmc1){ref-type="supplementary-material"}I). Conversely, there were specifically fewer mucosal IL-17A-producing CD4^+^ αβ T cells and γδ T cells after aDSS in FcγRIIB-M-TG mice than in N-TG controls ([Figures 6](#fig6){ref-type="fig"}F and 6G). Little change in colonic B cells was observed after IL-1β blockade in *Fcgr2b*^−/−^ mice ([Figure S6](#mmc1){ref-type="supplementary-material"}J); however, there was a reduction in the severity of colitis ([Figure 6](#fig6){ref-type="fig"}H) and colonic neutrophil infiltration ([Figure 6](#fig6){ref-type="fig"}I), directly implicating this pathway in detrimental immune responses driven by dysregulated FcγR signaling.

Discussion {#sec3}
==========

IgG-positive cells were first described in colonic biopsies from IBD patients more than 40 years ago by [@bib7]. Despite subsequent confirmation of their commensal specificity ([@bib33]), there has been little widespread acceptance that commensal-IgG immune complexes play a pathogenic role in UC. The subsequent identification of *FCGR2A^∗^A519G* (dnSNP: rs1801274) as the most significant non-HLA genetic variant associated with UC in a Japanese GWAS ([@bib5]) further supports this concept. This non-synonymous SNP results in an amino acid substitution that alters IgG binding affinity, the low-affinity variant (FcγRIIA-R131) is protective in both candidate gene studies (odds ratio 0.70--0.84) ([@bib52], [@bib57]) and a meta-analysis of IBD GWASs ([@bib24]). Our study sheds light on the mechanisms underpinning these observations, demonstrating an increase in anti-commensal IgG and in the FcγR A:I ratio of mucosal immune cells in UC. The net functional effect of this is to lower the cellular activation threshold, rendering intestinal macrophages more readily activated by local IgG ICs---an effect significantly offset by the low-affinity FcγRIIA-R131.

The generic effects of cross-linking FcγR on monocyte and macrophage cytokine production have been widely studied over many years by ourselves and others ([@bib16], [@bib18]), including in intestinal macrophages ([@bib50]), demonstrating increases in TNFα, IL-6, IL-1β, IL-10, and TL1A, to name but a few. Of these many potentially pathogenic cytokines, our study specifically identifies IL-1β as a key driver of IgG-associated inflammation in UC and reveals the molecular mechanisms underpinning this.

IL-1β correlates with disease severity in patients with IBD ([@bib30], [@bib41]), but its role in intestinal immunity is complex. Mice deficient in IL-1β exhibit a severe non-healing disease after DSS colitis, suggesting involvement in intestinal repair ([@bib8]). In contrast, IL-1β can promote chronic intestinal inflammation by inducing IL-17A-secreting innate lymphoid cells and Th17 cells ([@bib19]). Our data identify IL-1β as a key mediator of IgG- and FcγR-associated intestinal inflammation and show that it might act to induce type 17 immunity via effects on Th17 cells, γδ T cells and, potentially, group 3 innate lymphoid cells (although we did not specifically examine the latter here). We also found that IL-1β could have Th17-cell-independent effects, consistent with previous reports, for example, by promoting neutrophil and monocyte recruitment ([@bib20]). Notably, we observed IL-1β-dependent IL-17A and IL-22 production in both γδ and CD4^+^ αβ T cells, implicating both innate and adaptive T cell subsets in FcγR-driven mucosal inflammation. It will be of interest in future studies to determine the contribution of IgG-induced FcγR signaling to type 17 immunity in other models of intestinal inflammation, particularly those with a dominant role for adaptive T cells, for example, after T cell transfer into *Rag*^−/−^ mice. A careful description of Th17 cytokines in this model will be of clinical relevance, given reports that isolated IL-17A blockade can exacerbate intestinal inflammation ([@bib23]).

Although anti-commensal IgG, particularly anti-flagellin antibodies are present in CD, the association of FcγR variants with disease susceptibility is less robust than in UC ([@bib24]). Differential effects of genetic susceptibility loci in CD and UC are well recognized. For example, genetic variants that promote intracellular pathogen recognition and clearance are associated with CD and not with UC ([@bib1]). In this context, it is notable that the FcγRIIA-R131 polymorphism increases susceptibility to a number of infections ([@bib15]) and that IgG and FcγRs promote defense against mycobacterial infection ([@bib31]). Indeed, in mice, IgG and activating FcγRs are protective against the systemic spread of *Citrobacter rodentium*, an enteropathic bacteria ([@bib35]). Therefore, the deleterious effects of FcγRIIA-R131 on bacterial clearance might outweigh its beneficial, anti-inflammatory effects in CD.

Our data also have therapeutic implications, identifying IgG and activating FcγR signaling as potential therapeutic targets in UC. The only randomized controlled trial to investigate the use of B cell depletion in (treatment-resistant) UC has shown no benefit but is substantially under-powered with only n = 24 subjects ([@bib27]). Given that randomized trials of drugs licensed for IBD treatment typically require the inclusion of hundreds of patients to demonstrate efficacy ([@bib22], [@bib42]), the question of whether B cell manipulation might be of benefit in UC remains to be addressed. Agents to target activating FcγR signaling might be of utility and include Syk (spleen tyrosine kinase) inhibitors, which are currently being assessed in rheumatoid arthritis ([@bib53]) and glomerulonephritis ([@bib32]). Alternatively, application of an FcγRIIB agonist ([@bib10]) in UC would potentially decrease the FcγR A:I ratio, an effect functionally analogous to the presence of the low affinity FcγRIIA-R131. Our data suggest that targeting FcγR signaling in UC would have a potential advantage over single-cytokine blockade because of its impact on the production of multiple pro-inflammatory cytokines and chemokines. Finally, it is notable that a trial of IL-1R1 blockade using anakinra in acute severe UC (ISRCTN43717130) is underway in the UK ([@bib49]).

In summary, our study sheds light on the observed genetic association of FcγRIIA polymorphisms with UC, revealing the specific molecular mechanisms by which anti-commensal IgG augment inflammation and identifying novel therapeutic targets.

STAR★Methods {#sec4}
============

Key Resources Table {#sec4.1}
-------------------
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Contact for Reagent and Resource Sharing {#sec4.2}
----------------------------------------

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Menna R. Clatworthy (<mrc38@cam.ac.uk>).

Experimental Model and Subject Details {#sec4.3}
--------------------------------------

### Mouse strains {#sec4.3.1}

All mouse lines used here are on a C57BL/6 background. *Fcgr2b*^*−/−*^ mice were kindly provided by J. Ravetch (Rockefeller University) and S. Bolland (US National Institutes of Health, US National Institute of Allergy and Infectious Diseases (NIAID)) ([@bib9]). Macrophage transgenic (M-TG) and non-transgenic (N-TG) littermate controls were kindly provided by K.G.C. Smith. FcγRIIB overexpression was achieved using a construct in which FcγRIIB mRNA was placed under the control of the human CD68 promoter. NLRP3-deficient mice were kindly provided by Clare Bryant (University of Cambridge). C57BL/6, CD45.1^+^ C57BL/6 and *Rag2*^−/−^ mice were obtained from Jackson Laboratories (Margate, UK) and maintained inhouse for several generations. For the generation of bone marrow chimeras, recipient CD45.1^+^ C57BL/6 mice were lethally irradiated (2 × 5.5 G) followed by immediate tail intravenous (i.v.) injection of 2 × 10^6^ bone marrow cells from CD45.2^+^ C57BL/6 or CD45.2^+^ *Fcgr2b*^−/−^ mice. Recipient mice were checked for reconstitution after 8 weeks prior to commencement of colitis experiments. For all *in vivo* colitis experiments, 6 to 14-week old sex-matched mice were used and mice were co-housed throughout the duration of experiments. Both male and female mice were used. All M-TG and N-TG experiments were performed on littermates. In the case of non-littermate controls, mice were co-housed for at least 3 weeks prior to the initiation of experiments. Mice were maintained in specific pathogen-free conditions at a Home Office-approved facility in the UK. All procedures were carried out in accordance with the United Kingdom Animals (Scientific Procedures) Act of 1986.

### Human samples {#sec4.3.2}

Human ileal tissue was obtained from deceased donors with prior ethical approval (REC: 15/EE/0152). Samples were obtained from 2 male and 3 female donors aged 19-77. UC (n = 6) and healthy control (n = 6) stool samples were obtained locally (Addenbrooke's Hospital, Cambridge) with prior ethical approval (REC: 05/Q0108/355) from 6 male and 6 female donors and patient disease severity was scored using the Walmsley clinical activity index (CAI) ([Table S1](#mmc1){ref-type="supplementary-material"}). Peripheral blood mononuclear cells (PBMCs) were collected from blood leukocyte cones or healthy volunteers (*FCGR2A* SNP study) with prior ethical approval from the local ethics committee (REC: 08/H0308/176). Blood was obtained from 6 male and 6 female donors aged 24 to 55.

### Commensal strains {#sec4.3.3}

Commensal species were isolated from faeces of C57BL/6 mice and grown in LB medium at 37°C in a shaking incubator. *Parabacteroides distasonis* was grown in static culture in LB medium in an anaerobic cabinet.

Method Details {#sec4.4}
--------------

### DSS-induced experimental colitis {#sec4.4.1}

Colitis was induced the addition of 2% (*w*/*v*) 36,000-50,000MW DSS (MP Biomedicals) to drinking water for 6 days (acute DSS (aDSS)). Mice were culled at various time points up to day 28 following aDSS, as described in the text/figure legends. In some experiments, mice were subjected to a second 6-day course of 2% DSS after a two-week interval, termed chronic DSS (cDSS). Antibody was administered *in vivo* via i.p. injection (final volume, 200 μL sterile PBS). 1 mg InVivoMab anti-IL-1R1 IgG (JAMA-147; BioXCell) was given on day 0 and day 7 of a aDSS protocol. 0.5 mg anti-flagellin or control serum IgG was injected on day 0 of aDSS protocol. 0.5 mg rabbit anti-*Escherichia coli/Enterobactericeae* IgG (Abcam, ab137967) or PBS was injected on day 0 and day 3 of aDSS protocol. Colitis severity was monitored daily through changes in body weight, stool consistency, and intestinal hemorrhage. Moderate severity limits were imposed, with 20% weight loss or two moribund characteristics judged to be the severity threshold. At experimental endpoints, colon, spleen, MLN and blood were harvested and colitis severity further assessed through morphological changes in organs. The spleen, MLN, and colon were weighed, and colon length measured from cecum to rectum to determine length. The tissues were then processed for histology, RNA extraction, or flow cytometric analysis.

### Flagellin immunization {#sec4.4.2}

Flagellin immunization was carried out as previously described ([@bib26]). Briefly, C57BL/6 mice were hyperimmunized by two intraperitoneal (i.p.) injections with 10 μg of flagellin from *Salmonella typhimurium* (InvivoGen) in Incomplete Freund's Adjuvant (IFA) (Sigma Aldrich) two weeks apart. Mice were culled at four weeks and total serum IgG, as well as control serum IgG from unimmunized mice, was purified using Pierce Protein G purification columns (Thermo Fisher Scientific), as per the manufacturer's instructions.

### Murine primary cell isolation {#sec4.4.3}

Spleen, MLN, and colon were harvested and processed for single cell suspensions. Colons were dissociated from fat and luminal contents were gently removed. Tissues were opened longitudinally, cut into 0.5 cm pieces and washed by vortexing in ice-cold PBS with 10 mM HEPES. Tissue pieces were subsequently incubated with a stripping solution (RPMI-1640 medium containing 2% (*v*/*v*) FCS, 10 mM HEPES, 1 mM DTT, and 5 mM EDTA) at 37°C for two intervals of 20 min to remove epithelial cells, prior to enzymatic digestion in RPMI-1640 medium containing 1 mg/mL collagenase A (Sigma Aldrich) and 60 μg/mL DNase I (Roche). Tissue suspensions were mechanically dissociated and passed through a 70 μm cell strainer. Intestinal single cell suspensions were then harvested at the interface of a 40/80% (*v*/*v*) Percoll (Sigma-Aldrich) gradient and washed thoroughly in ice-cold PBS containing 3% (*v*/*v*) FCS before proceeding to further analysis. MLN and spleen suspensions were harvested by enzymatic digestion and mechanical tissue dissociation through a 70 μm filter. Splenic suspensions were subjected to red blood cell lysis (distilled H~2~O containing 0.83% (*w*/*v*) NH~4~Cl, 0.1% (*w*/*v*) NaHCO~3~, 100 μM EDTA) prior to washing twice in ice-cold PBS for analysis.

### Human primary cell isolation {#sec4.4.4}

Human LPMC isolation was carried out in a similar way to murine LPMC isolation. Tissue samples were opened longitudinally and cleaned of luminal contents. The mucosa was manually dissociated from the muscular layers, cut into small pieces and washed by vortexing in ice-cold PBS containing 10 mM HEPES. Epithelial cells and intraepithelial lymphocytes were removed by incubation in stripping buffer, as above, at 37°C for 1 h. The underlying tissues were then enzymatically digested for 1 h at 37°C in RPMI-1640 medium containing 0.42 mg/mL Liberase (Roche) or 1 mg/mL Collagenase A (Sigma-Aldrich), and 60 ug/mL DNase I (Roche), vortexed, and mechanically dissociated using a Gentle-MACS machine (Miltenyi Biotech). Dissociated tissue was then passed through a 70 μm cell strainer and centrifuged for 10 min at 1300 rpm. Intestinal single cell suspensions were harvested at the interface of a 40/80% (*v*/*v*) Percoll gradient and washed twice in ice-cold PBS containing 3% (*v*/*v*) FCS before proceeding to downstream applications.

### Flow cytometry {#sec4.4.5}

Single cell suspensions were blocked with 0.5% (*v*/*v*) heat-inactivated mouse serum followed by extracellular staining for 1 h at 4°C with a combination of the following antibodies. Murine antibodies: B220 (RA3-6B2, Thermo Fisher Scientific), CD3ε (145-2C11, Thermo Fisher Scientific), CD4 (GK1.5, Thermo Fisher Scientific), CD11b (M1/70, Thermo Fisher Scientific), CD11c (N418, Thermo Fisher Scientific), CD138 (DL-101, Thermo Fisher Scientific), CD19 (6D5, Biolegend), CD38 (90, Thermo Fisher Scientific), CD45.2 (104, Thermo Fisher Scientific), CX3CR1 (SA011F11, Biolegend), EpCAM (G8.8, Thermo Fisher Scientific), F4/80 (BM8, Thermo Fisher Scientific), FcγRI (X54-5/7, Biolegend), FcγRIIB (AT130-2, Thermo Fisher Scientific), FcγRIII (275003, R&D systems), FcγRIV (9E9, Biolegend), IgA (SouthernBiotech), IgD (11-26, Thermo Fisher Scientific), IgG (SouthernBiotech), IgG1 (A85-1, BD Biosciences), IgG2b (R12-3, BD Biosciences), IgG3 (R40-82, BD Biosciences), IgM (II/41, Thermo Fisher Scientific), Ly6C (HK1.4, Thermo Fisher Scientific), Ly6C/G (RB6-8C5, Thermo Fisher Scientific), MHC-II (M5/114.15.2, Thermo Fisher Scientific), TCR beta (H57-597, Thermo Fisher Scientific), and TCR gamma/delta (GL3, Biolegend). Human antibodies: CD14 (61D3, Thermo Fisher Scientific), CX3CR1 (2A9-1, Thermo Fisher Scientific), FcγRI (10.1, Thermo Fisher Scientific), FcγRIIA/B (CD32, Thermo Fisher Scientific), FcγRIIIA/B (eBioCB16, Thermo Fisher Scientific), IgA1/2 (G20-359, BD biosciences), and IgG (HP6017, Biolegend). Antibodies were used at a dilution of 1:200 in PBS. Viability staining was performed with LIVE/DEAD Fixable Aqua Dead Cell Stain kit (Thermo Fisher Scientific) for 20 min at room temperature. For biotinylated primary antibodies, secondary staining with streptavidin-conjugated PE (Thermo Fisher Scientific) or APC-eFluor780 (Thermo Fisher Scientific) was performed for 20 min at 4°C at a dilution of 1:300 in PBS. For intracellular cytokine staining, cells were incubated in RPMI-1640 medium containing 10% FCS, 1X penicillin-streptomycin (both Sigma-Aldrich), and 1X Brefeldin A (Thermo Fisher Scientific) solution for 3 h at 37°C, prior to fixation and permeabilization using the Intracellular Fixation and Permeabilization Buffer Set (Thermo Fisher Scientific) as per the manufacturer's instructions. Staining was carried out for 1 h at room temperature using a combination of the following antibodies: IL-17A (TC11-18H10.1, Biolegend), IL-22 (IL22JOP, Thermo Fisher Scientific), and pro-IL-1β (NJTEN3, Thermo Fisher Scientific). All antibodies were used at a 1:100 dilution. Cell counting was performed using 123count eBeads (Thermo Fisher Scientific). Flow cytometry data collection was performed on a Fortessa cytometer (BD biosciences) and data was analyzed using FlowJo software (Tree Star Inc.).

### Flow sorting {#sec4.4.6}

Murine intestinal macrophages were flow-sorted as live CD11b^+^ CX3CR1^+^ Ly6C^lo^ MHC-II^hi^ cells. Human ileal macrophages were flow-sorted as SSC^int^ CX3CR1^+^ CD14^+^ cells. Cell sorting was performed on FACS Aria Fusion (BD biosciences), iCyt Synergy (Sony Biotechnology Inc.), and MoFlo (Beckman Coulter) cell sorters. Data were analyzed using FlowJo software (Tree Star Inc.).

### Microbial flow cytometry {#sec4.4.7}

For murine stool samples, colonic fecal contents were homogenized in sterile PBS, briefly centrifuged at 1,000 rpm to remove large aggregates, and the resulting supernatant was washed twice in sterile PBS by centrifugation for 1 min at 8,000 rpm. At harvesting of commensal isolates, bacterial cultures were centrifuged for 10 min at 4000 rpm and used for downstream analyses. For all samples, bacterial pellets were resuspended in sterile PBS containing 1:50 dilution of mouse serum or PBS alone in 96-well v-bottom plates (Thermo Fisher Scientific) and incubated for 20 min at 4°C. For transgenic mouse serum anti-commensal IgG comparison, stool from *Rag2*-deficient mice was used, which lacks endogenous anti-commensal IgG. Human stool samples were processed as above, plated in 96-well v-bottom plates (Thermo Fisher Scientific) in sterile PBS, and centrifuged at 3,000 rpm for 10 min in a bench-top Sorvall centrifuge. For both human and murine samples, bacterial pellets or serum-opsonized bacteria were then resuspended in 50 μL sterile ice-cold PBS containing anti-mouse/human IgA-PE or anti-mouse/human IgG-Alexa 647 antibodies and stained for 20 min at 4°C. Cells were washed and resuspended in PBS or fixative containing 1:10,000 SYBR Green (Thermo Fisher Scientific) and analyzed by flow cytometry. Fecal and serum samples were paired from the same mouse, unless otherwise stated, and SYBR Green-high events were analyzed.

### Serum anti-commensal IgG ELISA {#sec4.4.8}

For serum anti-commensal IgG analysis, colonic fecal contents were processed as described above. Bacteria were homogenized using BugBuster 10X protein extraction reagent (Novagen), centrifuged at 20,000 *g* for 10 min, and the supernatant recovered for a crude commensal bacterial antigen preparation. Protein concentration was determined using the Pierce BCA protein assay kit (Thermo Fisher Scientific). Subsequently, 96-well Nunc ELISA plates (Thermo Fisher Scientific) were coated with 5 μg/mL commensal antigen preparation overnight at 4°C, washed extensively, and murine sera incubated in doubling dilutions for 4 h at room temperature. For small volumes of sera, samples were incubated at a 1:150 dilution. In the case of serum anti-flagellin IgG detection, 96-well Nunc plates were coated overnight with 200 ng/mL flagellin purified from *Salmonella typhimurium* (InvivoGen). Commensal antigen-specific IgG was detected using a goat anti-mouse IgG-horseradish peroxidase (HRP) conjugated antibody (Thermo Fisher Scientific, 1:10000 dilution), and TMB peroxidase substrate (BD biosciences). After 15-20 min, the reaction was quenched with 1 M Na~2~SO~4~ and the optical densities measured at 450 nm using a CLARIOstar spectrophotometer (BMG Labtech).

### Luminal IgG ELISA {#sec4.4.9}

Luminal contents were extruded using bicarbonate buffer (15 mM Na~2~CO~3~, 35 mM NaHCO~3~) containing cOmplete protease inhibitor (Roche). 96-well Nunc ELISA plates (Thermo Fisher Scientific) were coated with primary goat anti-murine IgG or goat anti-murine IgA antibodies (catalog numbers 1037-01 and 1040-01, respectively; SouthernBiotech) for 16 h at 4°C. Plates were extensively washed and incubated with luminal suspensions in serial dilutions for 4 h at room temperature. Bound IgG and IgA were detected using secondary goat anti-murine IgG and goat anti-murine IgA antibodies conjugated to HRP (catalog numbers 1037-05 and 1040-05, respectively; SouthernBiotech) and TMB peroxidase substrate (BD biosciences). Ig concentration was determined using a standard curve of murine IgG (I5381-5mg; Sigma-Aldrich) or murine IgA (14-4762-81; Thermo Fisher Scientific). Ig levels were normalized to total luminal protein content, as determined using the Pierce BCA protein assay kit (Thermo Fisher Scientific).

### Macrophage and intestinal immune cell culture {#sec4.4.10}

For murine BMDMs, bone marrow was flushed from the femur and tibia of mice using ice-cold sterile PBS and the subsequent cell suspension treated with red cell lysis buffer. Treated cells were then washed in ice-cold sterile PBS. BMDMs were generated by incubation of bone marrow cells in RPMI-1640 medium containing 10% FCS and 1X penicillin-streptomycin (both Sigma-Aldrich) (referred to as complete RPMI) supplemented with 100 ng/mL murine macrophage colony-stimulating factor (M-CSF; Peprotech). M-CSF-supplemented culture medium was replaced on day 3 and BMDMs were harvested on day 5-6. BMDMs were primed with 20 ng/mL murine granulocyte-macrophage colony-stimulating factor (GM-CSF; Peprotech) for 16 h prior to stimulation. For human MDM culture, diluted blood was overlaid on Histopaque 1077 (Sigma-Aldrich) in a 50 mL centrifuge tube and centrifuged for 20 min at 2,000 rpm at room temperature. The PBMC layer was removed and resuspended in cold complete RPMI. PBMCs were incubated in complete RPMI medium supplemented with 100 ng/mL human M-CSF (Peprotech). Additional M-CSF-supplemented media was added at day 3 and adherent macrophages were harvested at day 6.

Flow-sorted intestinal MNPs were plated in complete RPMI-1640 medium at a density of 0.5-1 × 10^5^ cells per well in 96-well round-bottom plates (Sigma-Aldrich) prior to stimulation. LPMC suspensions were plated in complete RPMI-1640 medium at a density of 5x10^5^-1x10^6^ cells per well in 24-well plates (Sigma-Aldrich) prior to *ex vivo* stimulation with Ova-IC or Ova. Cells were then washed extensively, and analyzed by qPCR, ELISA, and flow cytometry.

### IgG stimulation {#sec4.4.11}

For IgG IC stimulation, model Ova-IC was generated by opsonization of 40 μg/mL endotoxin-free ovalbumin (Ova; Hyglos) with 1.2-2 mg/mL polyclonal rabbit anti-Ova IgG antibody in serum (Sigma-Aldrich) at 37°C for 1h. Immune cells were stimulated in complete RPMI with Ova, anti-Ova serum, or Ova-IC at 37°C in a 5% CO~2~ incubator for 4 h for RNA analysis, including RNA-seq and quantitative PCR (qPCR), or 16 h for cytokine and chemokine ELISAs. For BMDM IL-1β production, 5 × 10^5^ murine BMDMs were stimulated with Ova or Ova-IC for 4 h at 37°C followed by 30 min stimulation with 2.5 mM ATP (Sigma-Aldrich).

For human c-IgG stimulation, 96-well high-affinity Nunc MaxiSorp plates (Thermo Fisher Scientific) were coated with 2 μg/mL human IgG (Sigma-Aldrich) overnight at room temperature. Plates were blocked with PBS containing 10% FCS for 1 h. Macrophages were plated at 0.5-1x10^5^ cells per well in triplicate in complete RPMI and additionally stimulated with 100 ng/mL LPS from *E. coli* (Sigma-Aldrich) or fecal commensal extract from healthy human donors harvested as above and outlined previously ([@bib44]). Supernatants were harvested after 24 h and analyzed by ELISA. In certain experiments, macrophages were pre-incubated for 30 min at 37°C with 20 μg/mL anti-FcγRIIA blocking antibody (R&D systems) and subsequently maintained at 5 μg/mL in culture with additional stimuli. Mitochondrial ROS were blocked using 0.5 mM MitoTEMPO (Sigma-Aldrich).

### Trim-Away {#sec4.4.12}

Human MDMs were electroporated with PBS, mouse anti-GFP (9F9.F9; Abcam) or mouse anti-NLRP3 (Cryo-2; Adipogen) IgG antibodies. All antibodies used for electroporation were passed through Amicon Ultra-0.5 100 kDa centrifugal filter devices (Millipore) to remove traces of azide and replace buffer with PBS. All antibodies were diluted to 0.6 mg/mL in PBS prior to electroporation. Antibody electroporation was performed using the Neon Transfection System (Thermo Fisher Scientific). MDMs were washed with PBS and resuspended in Buffer R (Thermo Fisher Scientific) at a concentration of 1.4 × 10^8^ cells/mL. For each electroporation reaction 1.4 × 10^6^ cells (10 μl) were mixed with 2 μl of antibody or PBS. The mixture was taken up into a 10 μl Neon® Pipette Tip (Thermo Fisher Scientific) and electroporated using the following settings: 1400V, 20 ms, 2 pulses. Electroporated cells were transferred to growth medium without antibiotics.

### Immunoblotting {#sec4.4.13}

MDMs were plated and stimulated as indicated previously in serum-free medium. 500 mL of supernatants was collected and precipitated using Methanol/Chloroform extraction. 500 mL MeOH and 125 mL Chloroform was added to 500 mL cell-free supernatant, vortexed briefly and spun at 13 000 g for 5 min. The upper layer was removed and a further 500 mL MeOH added to each sample, vortexed and spun at 13 000 g for 5 min. The supernatant was completely aspirated and the protein pellet was resuspended directly in NuPAGE LDS Sample buffer with 100 mM DTT and heated at 95°C for 10 min. MDMs were lysed in RIPA buffer (CST-9806) supplemented with a protease inhibitor cocktail (Roche), spun at 14000 g for 10 min and cleared lysates mixed with NuPAGE LDS Sample Buffer and heated at 95°C for 10 min. Samples were run on NuPAGE 4%--12% Bis-Tris gels (Thermo Fisher) and transferred onto nitrocellulose membrane. Antibody incubations were performed in PBS with 5% (*v*/*v*) milk and 0.1% (*v*/*v*) Tween-20. The primary antibodies used were goat anti-IL-1β IgG antibody (BAF201, R&D Systems, 1:500), mouse anti-NLRP3 (Cryo-2; Adipogen; 1:500), rabbit anti-ASC (AL177; Adipogen; 1:500), mouse anti-TRIM21 (D-12; Santa Cruz Biotechnology; 1:500) and rabbit anti-COXIV (LI-COR; 1:5000). HRP-coupled secondary anti-goat (Santa Cruz, sc-2056), anti-mouse (Dako), anti-rabbit (Thermo Fisher Scientific), and anti-β-actin (Sant Cruz, sc-47778) antibodies were detected by enhanced chemiluminescence (Amersham, GE Healthcare) and X-ray films.

### *FCGR2A* genotyping {#sec4.4.14}

DNA was extracted from whole blood of healthy volunteers using the Quick-DNA Universal kit (Zymo Research) as per the manufacturer's instructions. Genotyping was performed using the TaqMan Genotyping Master Mix (Thermo Fisher Scientific) and SNP Genotyping Assay probes for *FCGR2A* SNP rs1801274 (Thermo Fisher Scientific) as per the manufacturer's instructions by qPCR.

### RNA extraction and reverse transcription {#sec4.4.15}

RNA extraction was carried out using commercially available kits as per the manufacturer's instructions. QIAGEN RNeasy micro kits were used for cell numbers below 5 × 10^5^. The PureLink RNA mini kit (Thermo Fisher Scientific) was used for cell numbers over 5 × 10^5^. For whole tissue RNA extraction, tissue pieces were first disrupted using a Precellys 24 Homogenizer (Bertin Instruments), before extraction using the PureLink RNA mini kit (Thermo Fisher Scientific). RNA concentration and purity were determined using a NanoDrop spectrophotometer (Thermo Scientific) prior to cDNA synthesis using a High-Capacity RNA-to-cDNA kit (Applied Biosystems).

### Quantitative polymerase chain reaction {#sec4.4.16}

All qPCR was carried out in triplicate with Taqman reagents and the following pre-designed TaqMan Gene Expression Assay primers and probes (Thermo Fisher Scientific). Murine primers: *Ccl2* (Mm00441242_m1), *Csf2* (Mm01290062_m1), *Cxcl1* (Mm04207460_m1), *Cxcl2* (Mm00436450_m1), *Fcer1g* (Mm02343757_m1), *Fcgr1* (Mm00438874_m1), *Fcgr2b* (Mm00438875_m1), *Fcgr3* (Mm00438882_m1), *Fcgr4* (Mm00519988_m1), *Gapdh* (Mm99999915_g1), *Hprt* (Mm03024075_m1), *Ifng* (Mm01168134_m1), *Il1b* (Mm00434228_m1), *Il6* (Mm00446190_m1), *Il10* (Mm01288386_m1), *Il17a* (Mm00439618_m1), *Il22* (Mm01226722_g1), *Il23a* (Mm00518984_m1), *Tnf* (Mm00443258_m1), and *Tnfsf15* (Mm00770031_m1). Human primers: *CXCL8* (Hs00174103_m1), *FCER1G* (Hs00175408_m1), *FCGR1B* (Hs02341825_m1), *FCGR2A* (Hs01013401_g1), *FCGR2B* (Hs01634996_s1), *FCGR3A* (Hs02388314_m1), *FCGR3B* (Hs04334165_m1), *GAPDH* (Hs02786624_g1), *HPRT1* (Hs02800695_m1), and *IL1B* (Hs01555410_m1). qPCR was carried performed on the Viia 7 PCR machine (Life Technologies). Gene expression was normalized to *Gapdh* or *Hprt* using the 2^-ΔCt^. The 2^-ΔΔCt^ method was used for normalization between experimental conditions and genotypes.

### Cytokine/chemokine ELISA {#sec4.4.17}

Quantification of human and murine cytokines and chemokines in culture supernatants was carried out using commercially available R&D systems Duoset ELISA kits, as per the manufacturer's instructions.

### Immunofluorescence {#sec4.4.18}

Intestinal tissues were fixed with 1% (*w*/*v*) paraformaldehyde (Electron Microscopy Services) in PBS for 16 h, washed with PBS, and equilibrated in 30% (*w*/*v*) sucrose for a further 16 h. Tissues were then frozen at −80°C in Optimal Cutting Temperature (OCT) embedding medium (Thermo Fisher Scientific). Cryostat sections were cut at a thickness of 20-30 μm, air-dried for 1 h, then rehydrated for 10 min in PBS and blocked with a 0.1 M Tris solution containing 1% (*w*/*v*) mouse serum, 1% (*w*/*v*) bovine serum albumin (BSA), and 0.1% (*w*/*v*) Triton X-100 for 1 h at room temperature. Sections were stained overnight at 4°C with a combination of the following antibodies in blocking buffer at a 1:100 dilution: CD45.2 (104; Thermo Fisher Scientific), IgG (SouthernBiotech), and Ki67 (SolA15; Thermo Fisher Scientific). Additionally, actin was stained in certain experiments using Phalloidin dyes (Thermo Fisher Scientific) at a 1:200 dilution. Confocal imaging was carried out on a Leica SP8 confocal microscope. Images were analyzed using Imaris software (Bitplane).

### RNA-seq sample preparation {#sec4.4.19}

Flow-sorted CX3CR1^+^ CD11b^+^ Ly6C^lo^ MHC-II^+^ macrophages were plated at a density of 1 × 10^5^ cells per well in 96-well round-bottom plates and stimulated with Ova or Ova-IC for 4 h at 37°C in a 5% CO~2~ incubator. Following stimulation, cells were transferred into 750 μL RLT plus buffer (QIAGEN). Samples were immediately vortexed, snap frozen on dry ice and stored at −80°C. RNA was extracted from cell lysates using the RNeasy plus micro kit (QIAGEN) as per the manufacturer's instructions. Optimal DNA depletion columns (QIAGEN) were used to remove contaminating genomic DNA. Purified RNA was eluted in nuclease free water (Ambion) and stored at −80°C. Quality and concentration of the purified RNA was assessed using an RNA pico chip (Applied Biosystems) using a Bioanalyzer 2000 (Applied Biosystems) as per the manufacturer's instructions. For all RNA-seq experiments, samples had an RNA integrity number greater than 8, indicating minimal degradation of the RNA. For the preparation of libraries, SMARTer stranded total RNA-Seq mammalian pico input kit (Takara) was used as per the manufacturer's instructions. To produce the libraries, 1.5-3.55 ng of total RNA was used and libraries were amplified for 14 cycles of PCR. Library size was assessed using 1 μL of undiluted final libraries with a High Sensitivity DNA chip (Applied Biosystems) using a Bioanalyzer 2000 (Applied Biosystems) as per the manufacturer's instructions. Library concentration was quantified by PCR using 1/10000 dilution of the library in nuclease free water (Ambion) with ROX low KAPPA library quantification kit (KAPPA Biosystems). Libraries were pooled at an equimolar concentration with up to 12 libraries per pool.

### RNA sequencing and analysis {#sec4.4.20}

Sequencing of the libraries was carried out using a Hiseq 2500 (Illumina) on a 2x100bp sequencing run with 1 pool per flow cell lane. Sequencing was carried out at Genewiz (NJ, USA). Pooled libraries were de-multiplexed by Genewiz using Casava (Illumina) before transfer of the data to the University of Cambridge. Fastq files were trimmed of the first 3 nucleotides of the R1 strand and contaminating adaptor sequences and poor-quality bases removed (bases with a phred 33 score of \< 30) using trimgalore! (Babraham bioinformatics) and quality of the resulting files was assessed using FastQC (Babraham bioinformatics). Fastq files were aligned to the mm10 genome (Downloaded from <https://genome-euro.ucsc.edu/cgi-bin/hgGateway?db=mm10&redirect=manual&source=genome.ucsc.edu> on 18th January 2016) using hisat2. All analysis was carried out using R version 3.2.4. Reads were counted and assigned to genes using the Featurecount function from the RSubread package. Differential expression analysis was carried out using DESeq2 using a linear model with an appropriate design matrix following the default workflow. Resulting figures were plotted using ggplot2 and heatmap.2 from the gplots package. GSEA was performed for RNA-seq data by first assigning a rank metric to each gene using the following formula:$$\text{Rank}\ \text{metric}\  = \ 1\left( {\text{P}\ \text{value}\  + \ 1\text{x}10^{- 300}} \right) \ast \left( {\left| \text{LFC} \right|/\text{LFC}} \right)$$

GSEA was then run using GSEA 2.1 using the pre-ranked option with the classic setting against either gene sets from the molecular signature database or custom gene sets indicated in the text. FcγR gene lists were obtained from the Molecular Signature Database (MSigDB; <http://software.broadinstitute.org/gsea/msigdb>). Gene ontology analysis was carried out using TopGo. Selected populations were compared for enrichment to a gene universe which contained only genes which had a possibility of being present in both UC microarray and macrophage Ova-IC RNA-seq groups. Enriched GO terms were identified using a Fisher elim method.

### Microarray {#sec4.4.21}

Publicly available microarray datasets were downloaded from GEO (<https://www.ncbi.nlm.nih.gov/geo/>) along with appropriate chip annotation data. All analyses were carried out using R. All datasets were downloaded as raw intensity matrices. Data was normalized using RMA and limma. Probes were reduced to one probe per gene by selecting the probe with the greatest variance across the samples using the gene filter package. Differential expression was varied out using limma with an appropriate design matrix. GEO: [GSE59071](ncbi-geo:GSE59071){#intref0370} ([@bib51]), GEO: [GSE38713](ncbi-geo:GSE38713){#intref0375} ([@bib40]) and GEO: [GSE9452](ncbi-geo:GSE9452){#intref0380} ([@bib39]) datasets were used for human UC analysis, GEO: [GSE16879](ncbi-geo:GSE16879){#intref0385} ([@bib3], [@bib4]) for infliximab-resistant UC analysis (see also [Table S2](#mmc1){ref-type="supplementary-material"}), GEO: [GSE42768](ncbi-geo:GSE42768){#intref0390} ([@bib11]) for analysis of murine DSS-induced colitis, and GEO: [GSE49109](ncbi-geo:GSE49109){#intref0395} for *C. rodentium* infection analysis ([@bib34]). The *IGH* expression score was calculated as a sum of the normalized log2-transformed expression values of all *IGH*-containing probes in each sample. AUROC analysis was performed on normalized log2-transformed expression values of *FCGR2A* or the *IGH* expression score using GraphPad Prism 6. GSEA was performed as for RNA-seq without pre-ranking against either gene sets from the molecular signature database or custom gene sets indicated in the text.

### Hierarchical clustering {#sec4.4.22}

R and the base stats package were used for all calculations. Plots were generated using the package dendextend. For clustering analysis, the RMA normalized intensity for the genes of interest (all cytokines plus *FCGR2A*) were selected and a distance matrix calculated using Euclidean distance using the function "dist." The samples were subsequently hierarchically clustered using the function "hclust" using the complete method. To define clusters, the tree was cut into k clusters at a given height based on visual interpretation of the dendrogram (typically k = 4-5). The cluster containing *FCGR2A* was examined further.

### Single cell RNA-seq {#sec4.4.23}

Publicly available normal colonic mucosa single cell RNA-seq raw count data ([@bib29]) was acquired from GEO (GSE81861). Data was analyzed in R using the Seurat package. Genes with very low expression were discarded (average counts \< 0.4). Data was log-normalized using global scaling, and AUROC test was used to generate a ranked list of cell type-specific genes and associated scores. Peripheral blood mononuclear cell raw count data ([@bib58]) was acquired from the 10X genomics data portal (<https://support.10xgenomics.com/single-cell-gene-expression/datasets>) -- Donor A 68K PBMC. Data was log-normalized using global scaling in the Seurat package. Thereafter we detected highly variable genes with average log expression values between 0.01 and8 using the FindVariableGenes function in Seurat. We extracted the top 20 cell loadings after principal components analysis on the expression matrix subsetted to variable genes and generated a UMAP embedding from these loadings. We clustered the resulting k-nearest neighbor graph using Louvain clustering with default settings and annotated clusters based on marker genes defined by the AUROC test. The top 50 marker genes for each annotated cell type were used to calculate a rank-based enrichment score for single cells in the gut dataset, using the AUCell package ([@bib2]).

Quantification and Statistical Analysis {#sec4.5}
---------------------------------------

Statistical analysis was performed using GraphPad Prism software or R. For *in vivo* colitis experiments, comparison between experimental groups was performed using a nonparametric Mann-Whitney-U test, unless otherwise stated, and medians are indicated. For *in vitro* stimulation experiments, mean ± standard error of mean (SEM) are shown and a parametric Student's two-tailed t test or two-way ANOVA with Tukey's multiple comparisons test was used, unless paired samples were used, where a ratio paired t test was used. For correlations of RNA expression levels, linear regression analysis was used. For RNA-seq bioinformatics analyses, *P value*s were calculated using the standard DESeq 2 method with multiple correction using BH. For microarray experiments, *P value*s were calculated using the limma package with multiple correction using BH. ^∗^ p \< 0.05; ^∗∗^ p \< 0.01; ^∗∗∗^ p \< 0.001; ^∗∗∗∗^ p \< 0.0001. Sample sizes (*n*) for all shown data can be found in the figure legends. *In vitro* stimulations were performed in triplicate, unless stated, and sample sizes for *in vivo* experiments were determined based on initial experiments.

Data and Software Availability {#sec4.6}
------------------------------

The accession number for the data in this paper is GEO: [GSE109040](ncbi-geo:GSE109040){#intref0405}.
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